Following a hold-up and a remarkably divisive meeting, a federal vaccine advisory panel was scheduled to decide on Friday concerning altering the enduring advisory that every infant be inoculated against hepatitis B.
Intense Discussion and a Delayed Ballot
The opening session of the meeting on Thursday was marked by heated debate over restricting access to the hepatitis B vaccine for infants and a decision to delay the ballot by a day to provide committee members extra time to examine the language. The committee, which guides the Centers for Disease Control and Prevention on immunization practices, had put off the vote twice in the past.
“Is there any specific evidence of damage of giving this shot before 30 days? Or is this theory?” inquired one committee member.
In reply, another participant stated, “There is limited evidence about the prolonged hazard.”
Present Protocol and Possible Consequences
The vaccine is currently suggested for each baby within 24 hours of being born to halt contraction of hepatitis B, which can cause serious liver damage. It has been administered to over a billion individuals for in excess of thirty years.
The Atlanta conference presented no new evidence of harms caused by the vaccine. Authorities state any alteration to the current hepatitis B immunization timeline could have profound and widespread implications for infant and child health in the United States.
Group Membership and New Appointments
The expert committee can only make recommendations to the head of the CDC. The group's roster has experienced alterations in recent days, with the declaration that the group's former head would step down for an official role and be succeeded by a cardiac doctor who has been skeptical about other vaccines.
The board includes a number of immunization doubters who support a desire to overhaul – and perhaps, in some cases, eliminate – long-established vaccine advisories.